Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 15/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16634160 | 1.00 | TLR9 (0.48) | TLR9TLR7TLR8HTR1AKDM4E | |
| SCHEMBL16633393 | 0.94 | TLR9 (0.48) | TLR9TLR7TLR8HTR1AKDM4E | |
| SCHEMBL16633390 | 0.94 | TLR9 (0.48) | TLR9TLR7TLR8HTR1AKDM4E | |
| SCHEMBL16633387 | 0.91 | TLR9 (0.49) | TLR9TLR7TLR8HTR1AKDM4E | |
| SCHEMBL16633388 | 0.91 | TLR9 (0.49) | TLR9TLR7TLR8HTR1AKDM4E | |
| SCHEMBL16633840 | 0.91 | TLR9 (0.50) | TLR9TLR7TLR8ACVR1 | |
| SCHEMBL16633838 | 0.91 | TLR9 (0.50) | TLR9TLR7TLR8ACVR1 | |
| SCHEMBL25699825 | 0.91 | TLR9 (0.50) | TLR9TLR7TLR8ACVR1 | |
| SCHEMBL16633703 | 0.90 | TLR9 (0.47) | TLR9TLR7TLR8ACVR1 | |
| SCHEMBL16633088 | 0.90 | TLR9 (0.49) | TLR9TLR7TLR8ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | claimed |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-10 | — | — | US | claimed |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-16 | — | — | US | claimed |
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | TLR9 4/4885TLR7 2/4885TLR8 3/4885 |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | TLR9 4/4885TLR7 2/4885TLR8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.